US-based international pharmaceutical company Pfizer estimates a total of $54 billion revenue from its COVID-19 vaccine and oral pill sales this year, according to its financial results statement released Tuesday.
The company said it expects approximately $32 billion from vaccine doses to be delivered under its contracts signed as of late January.
An additional $22 billion revenue is expected from the company's antiviral coronavirus oral treatment pill Paxlovid.
Pfizer saw its revenue rise to $23.8 billion in the fourth quarter of 2021, soaring 105% from $11.6 billion in the same period of the previous year.
For the full year of 2021, revenue almost doubled to $81.3 billion from $41.6 billion in 2020, the financial results statement showed.